Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result

Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data

Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial